Updates Center

• 
  COMPANY ANNOUNCEMENT

  AtaGenix Laboratories Co., Ltd. issues a formal statement addressing the unauthorized use of its name by Wuhan Biolab-reagent, which forged documents and official seals, constituting illegal activity and unfair competition. The company clarifies that no business agreements exist with Wuhan Biolab-reagent, condemns their actions, and reserves the right to pursue legal action under Chinese intellectual property and criminal laws. AtaGenix advises partners to verify document authenticity to avoid legal and financial risks, reaffirming its commitment to honest operation and industry fairness.
• 
  International Life Sciences Leaders Visit AtaGenix: Advancing Antibody R&D with Velocity and Rigor

  On October 14, 2025, AtaGenix in Wuhan, China, welcomed global life sciences representatives to explore its 6-month antibody R&D platform, marking a biotech collaboration milestone.
• 
  AtaGenix March 2026 Research Highlights: Collaborative Breakthroughs Published in Top Journals

  In March 2026, AtaGenix supported multiple groundbreaking studies that were successfully published in high-impact journals including Cancer Research, Nature Communications, Cell Reports Medicine, and Nature Sensors. These collaborative achievements span key areas such as colorectal cancer immune evasion, dendritic cell immunosuppression, centrosome maturation, HE4-mediated PD-L1 regulation, and ultrasensitive nanobody-based FET biosensors for endometrial cancer detection. By providing highly specific custom antibodies and nanobodies, AtaGenix played a crucial role in validating novel molecular mechanisms and advancing innovative diagnostic and therapeutic strategies in life sciences.
• 
  AI-Powered Antibody Discovery: AtaGenix Leverages Cutting-Edge Technology to Slash Development Timelines

  On October 14, 2025, the biopharmaceutical industry is being reshaped by AI-driven antibody design, slashing development timelines from months to weeks with up to 100-fold efficiency gains. AtaGenix Laboratories leverages DeepMind’s AlphaFold to tackle complex CDR regions, generating high-affinity antibodies (Kd < 1 nM) for targets like GPCR and PD-L1. By integrating AI with robust wet-lab validation, including phage display and single B-cell cloning, AtaGenix mitigates data scarcity issues and reduces costs to <5% of traditional methods. Emerging tools like Chai-2 further highlight the field’s potential, achieving zero-shot de novo design with 16-20% hit rates. AtaGenix’s approach empowers clients to shift focus from discovery to clinical execution, redefining drug discovery economics.
• 
  AbbVie and RemeGen Partner on Novel PD-1/VEGF Bispecific Antibody

  AbbVie and RemeGen have announced an exclusive licensing agreement to co-develop RC148, a novel PD-1/VEGF bispecific antibody with strong potential in advanced solid tumors such as NSCLC and CRC. This multi-billion-dollar deal highlights the explosive growth of bispecific antibodies in oncology immunotherapy, particularly when combined with ADCs. The article also provides market snapshots showing rapid growth in bispecific, ADC, and custom antibody markets, with AtaGenix positioned as a comprehensive service provider supporting these innovations.
• 
  AtaGenix Fabruary 2026 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  In February 2026, AtaGenix provided core technical support for multiple collaborative scientific research projects, with several research findings published in internationally renowned journals such as Developmental Cell, Cell Communication and Signaling, Phytomedicine, and Plant Physiology and Biochemistry. The research covers diverse fields including Arabidopsis thaliana, Platycodon grandiflorum, bladder cancer, and Grass Carp Reovirus (GCRV-II), focusing on regulatory mechanisms, bioactive component biosynthesis, cancer therapy, and viral immune evasion. AtaGenix supported these studies through custom antibody synthesis, protein expression, and purification services, laying a solid foundation for the efficient output of scientific research achievements and injecting impetus into life science innovation.
• 
  AtaGenix December 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  AtaGenix's December 2025 literature collection showcases two high-impact publications supported by its advanced protein and antibody technologies. The studies, published in Advanced Science (IF 14.1) and Molecular Therapy (IF 12), address critical challenges in neurogenic bladder fibrosis—identifying Itga8 as a key therapeutic target—and on-target/off-tumor toxicities in low-affinity Nectin-4-specific CAR-T therapy for solid tumors. These achievements highlight AtaGenix's vital role in enabling cutting-edge life science research and clinical translation.
• 
  AtaGenix Custom CENH3 Antibodies Power Centromere Research in 52+ Plant Species

  AtaGenix specializes in high-specificity custom CENH3 antibodies, successfully supporting centromere studies across more than 52 plant species, including Brassica crops, pepper, grape, jujube, and longan. Our antibodies have played a pivotal role in numerous high-impact studies involving telomere-to-telomere (T2T) genome assembly, ChIP-seq-based centromere mapping, pangenome analysis, and structural variant detection—revealing the dominant role of LTR retrotransposons in rapid centromere evolution and providing powerful tools for crop genetic improvement and functional plant genomics.
• 
  Visit AtaGenix at AACR 2026 (Booth #1761) – R&D service and catalog reagents for oncology studies

  Visit AtaGenix at AACR 2026 Booth #1761 in San Diego to explore custom CRO services for oncology drug discovery, including recombinant protein expression, antibody engineering, and stable cell lines. Discover abinScience's ready-to-use reagents: over 10,000 proteins and 20,000+ antibodies for immune checkpoints, tumor antigens, ADC/CAR-T, and biomarker studies. Accelerate your cancer research innovation.
• 
  AtaGenix November 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  In November 2025, AtaGenix proudly supported four high-impact publications spanning oncology, infectious diseases, and agricultural biotechnology. Featured research includes a novel ZUP1-targeted strategy to overcome olaparib resistance in triple-negative breast cancer, an engineered Mycoplasma pneumoniae strain that degrades dual-species biofilms, a low-cost Meta-SPR biomolecular detection platform, and the repurposing of clotrimazole as an eco-friendly fungicide against rice blast. Through recombinant protein purification, custom antibody development, and affinity validation services, AtaGenix continues to accelerate cutting-edge life science discoveries worldwide.